Sun Pharmaceutical Industries Ltd
NSE: SUNPHARMA BSE: 524715
₹1752.50
(0.89%)
Thu, 12 Mar 2026, 03:48 pm
Market Cap4170.19B
PE Ratio38.52
Dividend0.95
Health Technology
Pharmaceuticals: Major
24.5KSun Pharmaceutical Industries Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (3.9x coverage).
- Dividends after 3 years are expected to be well covered by earnings (6.3x coverage).
- Sun Pharmaceutical Industries's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Sun Pharmaceutical Industries's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Sun Pharmaceutical Industries's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Sun Pharmaceutical Industries's earnings are expected to exceed the low risk growth rate next year.
- Sun Pharmaceutical Industries's earnings are expected to increase by more than the low risk growth rate in 3 years time.
- An improvement in Sun Pharmaceutical Industries's performance (ROE) is expected over the next 3 years.
- Sun Pharmaceutical Industries's revenue growth is expected to exceed the India market average.
- Cash flow for Sun Pharmaceutical Industries is expected to increase but not above the 50% threshold in 2 years time.
- Sun Pharmaceutical Industries's earnings are expected to grow by 17.5% yearly, however this is not considered high growth (20% yearly).
- Sun Pharmaceutical Industries's earnings growth is positive but not above the India market average.
- Sun Pharmaceutical Industries's net income is expected to increase but not above the 50% threshold in 2 years time.
- Sun Pharmaceutical Industries is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Performance (ROE) is not expected to exceed the current IN Pharmaceuticals industry average.
- Sun Pharmaceutical Industries's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Sun Pharmaceutical Industries's revenue is expected to grow by 7.7% yearly, however this is not considered high growth (20% yearly).
health
- Sun Pharmaceutical Industries is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Sun Pharmaceutical Industries is profitable, therefore cash runway is not a concern.
- Sun Pharmaceutical Industries is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (88.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 4.3x debt.
- Sun Pharmaceutical Industries's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (31.5% vs 15.2% today).
- Interest payments on debt are well covered by earnings (EBIT is 16.3x coverage).
- Sun Pharmaceutical Industries's level of debt (15.2%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Sun Pharmaceutical Industries board of directors is about average.
- Dilip's remuneration is lower than average for companies of similar size in India.
- Dilip's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Sun Pharmaceutical Industries management team is about average.
misc
- Sun Pharmaceutical Industries has significant price volatility in the past 3 months.
past
- Sun Pharmaceutical Industries's 1-year earnings growth exceeds its 5-year average (41.1% vs -8.7%)
- Sun Pharmaceutical Industries's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (41.1% vs 22.7%).
- Sun Pharmaceutical Industries's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Sun Pharmaceutical Industries used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Sun Pharmaceutical Industries's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Sun Pharmaceutical Industries has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- 524715 matched the Pharmaceuticals industry (26.7%) over the past year.
- 524715 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524715 is up 7.6% along with the Pharmaceuticals industry (6.8%) over the past month.
- BSE:524715 is up 7.6% along with the India market (8%) over the past month.
- Sun Pharmaceutical Industries's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Sun Pharmaceutical Industries's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Sun Pharmaceutical Industries is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Sun Pharmaceutical Industries is poor value based on expected growth next year.
- Sun Pharmaceutical Industries is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Sun Pharmaceutical Industries is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800